Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
56.3M
-
Number of holders
-
100
-
Total 13F shares, excl. options
-
55.6M
-
Shares change
-
-1.99M
-
Total reported value, excl. options
-
$506M
-
Value change
-
-$43M
-
Put/Call ratio
-
1.31
-
Number of buys
-
57
-
Number of sells
-
-44
-
Price
-
$9.10
Significant Holders of Astria Therapeutics, Inc. - Common Stock, $0.001 par value per share (ATXS) as of Q2 2024
140 filings reported holding ATXS - Astria Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q2 2024.
Astria Therapeutics, Inc. - Common Stock, $0.001 par value per share (ATXS) has 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.6M shares
of 56.3M outstanding shares and own 98.69% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (6.49M shares), FMR LLC (6.05M shares), RA CAPITAL MANAGEMENT, L.P. (5.04M shares), VR Adviser, LLC (3.61M shares), Fairmount Funds Management LLC (3.55M shares), BlackRock Inc. (3.52M shares), Vestal Point Capital, LP (3.25M shares), TCG Crossover Management, LLC (2.76M shares), VANGUARD GROUP INC (2.59M shares), and Vivo Capital, LLC (2.33M shares).
This table shows the top 100 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.